Citizens Financial Group Inc RI Sells 809 Shares of Eli Lilly And Co (LLY)

Citizens Financial Group Inc RI lessened its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 1.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 72,071 shares of the company’s stock after selling 809 shares during the quarter. Citizens Financial Group Inc RI’s holdings in Eli Lilly And Co were worth $7,734,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. BlackRock Inc. raised its position in Eli Lilly And Co by 1.3% during the second quarter. BlackRock Inc. now owns 66,644,897 shares of the company’s stock valued at $5,686,808,000 after acquiring an additional 864,451 shares in the last quarter. Janus Henderson Group PLC raised its position in Eli Lilly And Co by 7.5% during the second quarter. Janus Henderson Group PLC now owns 10,008,768 shares of the company’s stock valued at $854,049,000 after acquiring an additional 700,582 shares in the last quarter. Morgan Stanley raised its position in Eli Lilly And Co by 37.8% during the second quarter. Morgan Stanley now owns 4,473,537 shares of the company’s stock valued at $381,727,000 after acquiring an additional 1,227,888 shares in the last quarter. Bank of Montreal Can raised its position in Eli Lilly And Co by 4.6% during the third quarter. Bank of Montreal Can now owns 4,330,654 shares of the company’s stock valued at $464,722,000 after acquiring an additional 191,374 shares in the last quarter. Finally, Swiss National Bank raised its position in Eli Lilly And Co by 2.3% during the second quarter. Swiss National Bank now owns 3,851,143 shares of the company’s stock valued at $328,618,000 after acquiring an additional 84,800 shares in the last quarter. 76.17% of the stock is currently owned by hedge funds and other institutional investors.

In other news, major shareholder Lilly Endowment Inc sold 3,587 shares of the business’s stock in a transaction on Friday, August 10th. The shares were sold at an average price of $103.06, for a total value of $369,676.22. Following the sale, the insider now owns 120,707,597 shares in the company, valued at approximately $12,440,124,946.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Alfonso G. Zulueta sold 6,000 shares of the business’s stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $106.31, for a total transaction of $637,860.00. Following the completion of the sale, the senior vice president now owns 55,224 shares in the company, valued at approximately $5,870,863.44. The disclosure for this sale can be found here. Insiders have sold 1,185,271 shares of company stock worth $123,843,752 in the last quarter. Corporate insiders own 0.11% of the company’s stock.

LLY opened at $106.75 on Monday. Eli Lilly And Co has a fifty-two week low of $73.69 and a fifty-two week high of $116.61. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40. The firm has a market cap of $114.65 billion, a price-to-earnings ratio of 24.94, a price-to-earnings-growth ratio of 1.73 and a beta of 0.29.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be paid a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, November 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.11%. Eli Lilly And Co’s dividend payout ratio is currently 52.57%.

Several equities analysts recently weighed in on LLY shares. Morgan Stanley lifted their price target on shares of Eli Lilly And Co from $93.00 to $102.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 31st. TheStreet lowered shares of Eli Lilly And Co from a “b” rating to a “c+” rating in a research report on Friday, August 24th. Guggenheim started coverage on shares of Eli Lilly And Co in a research report on Monday, October 8th. They issued a “buy” rating on the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $128.00 price target on shares of Eli Lilly And Co in a research report on Wednesday, October 17th. Finally, Barclays reissued an “overweight” rating and issued a $112.00 price target (up previously from $107.00) on shares of Eli Lilly And Co in a research report on Tuesday, September 18th. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $111.53.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Average Daily Trade Volume – What It Means In Stock Trading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply